133 results about "Immunohistochemistry" patented technology

The invention belongs to the technical field of medical diagnosis, and discloses a quantum multicolor immune digital pathological diagnosis analysis system, which comprises the following steps: acquiring high-resolution digital images of an immunohistochemical or immunofluorescence slice and a slide, and analyzing multicolor signal distribution in the images to obtain a quantum chromatographic image set; pixel-level color separation and intensity quantization are carried out on the quantum chromatographic image set, and a quantum intensity index set of each pixel is generated; performing multi-target color overlay analysis and post-translational modification protein specificity evaluation on the quantum intensity index set to construct a multi-color modification index set; identifying a single cell boundary and a multi-cell community based on the multicolor modification index set, and extracting a cell morphological parameter and a spatial adjacency relation to obtain a cell quantum analysis set; performing consistency correction and traceable recording by applying an automatic quality control mechanism, and generating a digital diagnosis report; the accuracy of accurate qualitative and quantitative analysis of immunohistochemistry and immunofluorescence is greatly improved.

The invention discloses pyruvate carboxylase (PC) serving as a biomarker for detecting endometriosis and application of the pyruvate carboxylase (PC) to treatment of the endometriosis. The biomarker can be used for detecting the expression level of PC in an endometrial tissue sample through an immunohistochemical method, and when the IHC score is greater than or equal to 4, a subject is judged to be at a high risk of endometriosis or suffered from the endometriosis. Meanwhile, the invention provides an application of drugs (including specific siRNA, ZY-444, octyl gallate and the like) for inhibiting PC expression in treatment of endometriosis, and a corresponding treatment method. The invention provides a new biomarker, target spot and scheme for detection and treatment of endometriosis, and has important clinical application value.

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

The invention relates to the technical field of biomedical image processing, and discloses a multi-fluorescence immunohistochemical image intelligent analysis method based on deep learning. The method comprises the following steps: acquiring image data through image acquisition equipment, and performing data integrity verification, format conversion and the like to obtain a standard image data set; performing noise removal and brightness equalization preprocessing on the image based on a preset rule, and extracting image features by using a deep learning model; and finally carrying out region segmentation and object identification according to the features. According to the method, full-process automation of multiple fluorescence immunohistochemical images from collection to analysis is realized, and the accuracy, efficiency and reliability of image analysis are effectively improved through standardized processing, adaptive preprocessing and deep learning feature extraction and analysis of image data; powerful technical support is provided for biomedical research and clinical diagnosis, and the method has important application value.

A reagent kit, staining method, and application for combining dual immunohistochemistry with elastin fiber staining. The reagent kit includes a combination of primary antibodies, consisting of anti-CK7 and anti-CD34 monoclonal antibodies from different species, such as rabbit anti-human CK7 monoclonal antibody and mouse anti-human CD34 monoclonal antibody. By selecting CK7 and CD34 as the primary antibody combination, the growth pattern of tumor epithelium can be accurately indicated, and the proliferation and thickening of alveolar septal fibrous tissue caused by tumors can be clearly revealed, as opposed to structural changes of alveoli induced by other factors. Combined with independent Victoria blue staining, the elastin fibers of the walls of arteries and veins, as well as the pleura of the lungs, can be clearly visualized, aiding in the assessment of the integrity of elastin fibers on the lung surface and in determining the extent of tumor infiltration.

Methods and systems for analysing the cellular composition of a sample are described, comprising: providing an image of the sample in which a plurality of cellular populations are associated with respective signals and classifying a plurality of query cells in the image between a plurality of classes corresponding to respective cellular populations in the plurality of cellular populations. This is performed by providing a query single cell image to an encoder module of a machine learning model to produce a feature vector for the query image, and assigning the query cell to one of the plurality of classes based on the feature vector for the query image and feature vectors produced by the encoder module for each of a plurality of reference single cell images. The machine leaning model comprises: the encoder module, configured to take as input a single cell image and to produce as output a feature vector the single cell image, and a similarity module configured to take as input a pair of feature vectors for a pair of single cell images and to produce as output a score indicative of the similarity between the single cell images. Thus, the machine learning model can be obtained without the need for an extensively annotated dataset. The methods find use in the analysis of multiplex immunohistochemistry / immunofluorescence in a variety of clinical contexts.

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

Microglial spatial heterogeneity remains a crucial yet poorly studied question in light of potential cell-directed therapies for Alzheimer`s disease (AD). Little is known about the dynamics of spatially distinct microglia states, which are either adjacent or non-associated with the plaque site, and their selective contributions to neurodegeneration in vivo. So far, research has essentially focused on pathology-associated microglia. Here, we combined novel multicolor fluorescence fate mapping, single-cell transcriptional analysis, epigenetic profiling, advanced immunohistochemistry and computational modelling to comprehensively characterize the relation of plaque-associated and non-plaque- associated microglia during neurodegeneration. This approach enabled us to identify and characterize non-plaque-associated microglia as a unique and highly dynamic microglial state in a mouse model of AD. Non-plaque-associated microglia modulate network expansion, quickly adapt to environmental cues and their transition to plaque-associated microglia can be specifically modulated during disease, contrary to their reputation as a passive bystander subpopulation. This description of the dynamics of spatially segregated microglial states and their distinct molecular features may therefore open promising new avenues for state-specific therapeutic interventions during neurodegeneration.

1. Name of the product in this design: Fully Automatic Immunohistochemistry Independent Temperature Controlled Individual Drop Staining Machine (CNT310). 2. Purpose of this design: For staining samples before pathological analysis. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present application relates to the technical field of incubation bin assembly, and aims to provide an incubation bin liquid discharge device and an immunohistochemical device to solve the technical problem of low liquid discharge efficiency of the incubation bin in the prior art, which affects incubation and reaction operation. The immunohistochemical device comprises a bottom plate and an incubation bin assembled on the bottom plate, and further comprises an incubation bin liquid discharge device assembled on the bottom plate, wherein the incubation bin liquid discharge device is connected with the incubation bin in correspondence, and the incubation bin liquid discharge device comprises a transfer bin and a liquid discharge channel connected at one end of the transfer bin, the other end of the liquid discharge channel is provided with a liquid inlet, and the liquid inlet is used for butting against a waste liquid pipe at the bottom of the incubation bin; a quick liquid discharge device is connected on the liquid discharge channel or the transfer bin, and the quick liquid discharge device is used for sucking the transfer bin to quickly suck the waste liquid in the waste liquid bin into the transfer bin.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-terminal deoxynucleotidyl transferase (TdT) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody disclosed by the invention can specifically recognize TdT protein naturally expressed in cells and tissues, has the advantages of high specificity, high affinity, high sensitivity and the like when being used for immunoblotting, immunohistochemistry and other immunodetection systems, is beneficial to reducing false positive and false negative rates in pathological diagnosis, improves the accuracy of immunodiagnosis, and has a good application prospect. The method has wide application potential in the field of immunological detection of living biological samples. In addition, the antibody disclosed by the invention has cross-species reaction characteristics on homologous TdT proteins of human, mice and rats, so that the application scene of the antibody is greatly expanded.

This invention discloses an anti-MSLN antibody and its applications. The anti-MSLN antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3. The amino acid sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NO:7, 8, and 9, respectively; and the amino acid sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NO:4, 5, and 6, respectively. The antibody provided by this invention has good affinity and specificity for MSLN antigens, effectively detecting target proteins in cells overexpressing MSLN. It can also be widely used as a core ingredient in the development of high-sensitivity MSLN detection kits such as ELISA, Western blotting, and immunohistochemistry.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

The present invention discloses a multi-station assembly line for immunohistochemistry and HE atomization staining and sealing, comprising a housing, an incubation module, a cover template cleaning module, a mobile liquid adding module, a tray, a staining module, a centrifugal liquid throwing module, a glue sealing module and a high-temperature repair water bath module are arranged in the housing, the staining module and the glue sealing module are both located above the tray, the centrifugal liquid throwing module is located below the tray, and can drive the tray to rotate horizontally, an incubation module and a high-temperature repair water bath module are arranged outside the staining module, the tray can be moved to the incubation module and the high-temperature repair water bath module under the drive of a sliding conveying mechanism, and the staining module is isolated from the incubation module and the high-temperature repair water bath module by a movable isolation component, a cover template cleaning module that can move up and down is provided below the incubation module, and a mobile liquid adding module is provided above the incubation module. The equipment has a high degree of automation, good processing effect, high work efficiency, and saves a lot of labor costs.

The invention provides a multiplex fluorescence immunohistochemical detection kit for rare gastrointestinal tumors and application of the multiplex fluorescence immunohistochemical detection kit, and belongs to the technical field of multiplex immunohistochemistry. The invention provides a multiplex fluorescence immunohistochemical detection reagent combination, which comprises a monoclonal antibody designed for protein markers and a fluorescent dye, and can be applied to multiplex fluorescence immunohistochemical detection for detecting the protein markers such as PD-L1, PD-1, CTLA-4, LAG-3, TIM-3 and TIGIT. The invention further provides a kit capable of being used for multiplex fluorescence immunohistochemical detection, staining detection of six protein markers on a single section can be achieved, and multiplex fluorescence staining of disease samples, especially complex-structure gastrointestinal tract rare tumor samples is achieved by matching six protein targets according to a specific staining sequence and fluorescence channels. And false positive caused by staining crosstalk of each channel is prevented.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human prostate specific membrane antigen (PSMA) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody with the complementarity determining region sequence provided by the invention can specifically recognize PSMA expressed by cells and tissues, has good affinity in combination with the PSMA, has high recognition sensitivity, can effectively resist the interference of complex non-target protein components in the cells / tissues, has no specific combination with non-target antigens, is suitable for immunological detection of the PSMA, and has good application prospects. The kit is especially suitable for western blot detection and immunohistochemical methods, and can reduce the occurrence rate of false positive and false negative results and improve the accuracy of immunodiagnosis.

This invention discloses DLL3 as a therapeutic target for cervical neuroendocrine carcinoma and its application, belonging to the field of biotechnology. This invention discloses the specific expression of the DLL3 gene in cervical neuroendocrine carcinoma (NECC) and its application as a therapeutic target. Single-cell sequencing and immunohistochemistry revealed activation of the DLL3-NOTCH1 / 2 signaling axis in NECC, and functional experiments confirmed that it drives malignant progression by promoting tumor proliferation and inducing T cell exhaustion. Furthermore, this invention constructed an NECC organoid-TIL co-culture model to verify the synergistic efficacy of the DLL3-targeting drug AMG757 combined with EP chemotherapy. This invention provides new target selection and theoretical basis for the precision diagnosis and treatment of NECC, and has significant clinical translational value.

The application discloses a kind of detection Tgfβ1 to hepatolenticular degeneration neutrophil polarization method and application, including the following steps: step 1, by immunohistochemistry and immunofluorescence co-localization determine hepatolenticular degeneration mouse liver fibrosis formation process, hepatocyte high expression Tgfβ1;Step 2, by inhibiting the high expression of Tgfβ1 of hepatolenticular degeneration mouse liver fibrosis formation process, determine the mitigation of neutrophil polarization;Step 3, collect mouse bone marrow neutrophil, by real-time fluorescence quantitative PCR, protein electrophoresis and methylation reaction determine the mechanism of Tgfβ1 promote neutrophil polarization.The application can detect the effect of Tgfβ1 in hepatolenticular degeneration neutrophil polarization, facilitate to determine hepatolenticular degeneration liver lesion mechanism.

Immunohistochemistry (INC) and in situ hybridization (ISH) methods are used for the targeted detection and localization of biomolecules (e.g., proteins and miRNAs) in tissues or cells, for research applications and clinical applications such as those of pathologists (e.g., biomarker analysis of resected tumors or tumor biopsies). These methods include mass spectrometry imaging (MSI) as a mode for detecting and localizing biomolecules in tissues or cells. The methods employ optically cleavable mass-tagged reagents linked to probes such as antibodies and nucleic acids and used to enable multiplexed immunohistochemistry and in situ hybridization, with MSI as the detection / readout mode. The methods also include multi-omics MSI procedures in which MSI of optically cleavable mass-tagged probes is combined with other MSI modes, such as direct label-free MSI of endogenous biomolecules from biological samples (e.g., tissues).

This invention discloses an anti-MSLN antibody and its applications. The anti-MSLN antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3. The amino acid sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NO:7, 8, and 9, respectively; and the amino acid sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NO:4, 5, and 6, respectively. The antibody provided by this invention has good affinity and specificity for MSLN antigens, effectively detecting target proteins in cells overexpressing MSLN. It can also be widely used as a core ingredient in the development of high-sensitivity MSLN detection kits such as ELISA, Western blotting, and immunohistochemistry.

This invention belongs to the field of biomedicine and tumor immunotherapy technology, specifically relating to a monoclonal antibody targeting the immune checkpoint molecule CD276 (B7-H3) and its applications. The applicant conducted immunization and screening work around the human CD276 antigen, selecting two representative monoclonal antibody clones, 2B2-1 and 5G4-2, from multiple candidate antibodies. The nucleotide and amino acid sequences of their heavy and light chain variable regions were determined, and their performance in flow cytometry, T-cell killing assays, immunohistochemistry, ELISA, and Biacore affinity assays was systematically evaluated. Experimental results show that the above antibodies can specifically recognize and bind to CD276, efficiently distinguish between CD276-high and low-expressing cells, and enhance the killing activity of T cells against CD276-high expressing tumor cells in an in vitro co-culture system. This provides an excellent antibody backbone for the subsequent construction of diagnostic kits, ADC drugs, or bispecific antibodies.

This invention discloses an antibody (YWHG-4) against HLA-G isoform molecules HLA-G1, HLA-G4, and HLA-G5, and its uses. The antibody (YWHG-4) is produced from a hybridoma with accession number CCTCC NO:2021204, using the antigenic peptide (RGYYNQSEASSHTLQWMIGC) of amino acid position 106-126 of the HLA-G molecule heavy chain as the immunogen. This invention provides the nucleotide encoding the YWHG-4 antibody and its encoding amino acid sequence. Furthermore, this invention provides the uses of the YWHG-4 antibody for the detection of HLA-G isoform molecules HLA-G1, HLA-G4, and HLA-G5 using Western blotting, immunohistochemistry, ELISA, and flow cytometry.

The invention relates to the technical field of medical image processing and artificial intelligence, and particularly discloses an intestinal cancer pathological image screening method applied to fluorescence immunohistochemistry. The method comprises the following steps: carrying out multi-channel acquisition and pretreatment on a fluorescent pathological section; according to the method, the image screening model based on the convolutional neural network is constructed and trained, automatic screening and grading of pathological images are realized through the trained deep learning model, mass fluorescence immunohistochemical intestinal cancer pathological images can be processed in batches, manual evaluation one by one is not needed, the screening period is greatly shortened, and the screening efficiency is improved. The problems that traditional manual screening is low in efficiency and difficult to meet high-throughput image analysis requirements are solved. According to the automatic process, the workload of pathologists is reduced, fatigue errors caused by long-time manual screening are avoided, efficient and stable data screening support is provided for subsequent accurate quantitative analysis and AI model training, and efficient promotion of clinical pathological research and diagnosis is assisted.

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

The invention discloses a polymer nano-enzyme as well as a preparation method and application thereof. The nano-enzyme comprises a nano-enzyme core modified by a surface modifier and a dendritic polymer coupled with the surface modifier. The preparation method of the polymer nano-enzyme comprises the following steps: preparing a nano-enzyme precursor, and then washing the nano-enzyme precursor to obtain a first intermediate; the nano-enzyme precursor is a nano-enzyme core modified by a surface modifier; preparing a first intermediate dispersion liquid, and adding an activator dispersion liquid and a stabilizer dispersion liquid into the first intermediate dispersion liquid to obtain an activation system; the invention also discloses an application of the polymer nano-enzyme. The polymer nano-enzyme provided by the invention can be used as an enzyme label substitute to be widely applied to enzyme-linked immunosorbent assay, immunohistochemistry, immunochromatography, chemiluminescence and other biochemical detection methods, and signal amplification with high sensitivity, wide pH and high temperature tolerance is realized.

The invention discloses a canine PD-L1 monoclonal antibody, a hybridoma cell strain secreting the canine PD-L1 monoclonal antibody and application of the canine PD-L1 monoclonal antibody. The hybridoma cell strain is 3B4C7B2F10C10 preserved in the China Center for Type Culture Collection on June 24, 2025, the preservation number is CCTCC NO: C2025167, the hybridoma cell strain can stably secrete the antibody, and the dog PD-L1 monoclonal antibody can recognize the dog PD-L1 protein, has good color development in dog tumor immunohistochemistry, can accurately detect the expression degree of the PD-L1 in the dog tumor, and can be used for preparing the dog PD-L1 monoclonal antibody. The expression analysis of the PD-L1 has important significance on the clinical application of a PD-1 / PD-L1 inhibitor in dogs, the high expression of the PD-L1 can be used as an important marker for the immunotherapy effect of the dogs, and the expression level of the PD-L1 can be used as an important reference factor for clinical test design and treatment decision in the future. Meanwhile, reference is provided for immunohistochemical auxiliary diagnosis of tumor malignancy degree of dog tumors and dog PD-1 and PD-L1 monoclonal antibody mediated dog tumor immunotherapy prognosis, and the application prospect is huge.

The application discloses a goat recombinant monoclonal antibody against rabbit IgG and a preparation and application thereof, and belongs to the technical field of biotechnology. The recombinant monoclonal antibody is obtained by taking purified rabbit serum IgG as an immunogen, immunizing a goat, screening specific B cells, and obtaining a heavy chain variable region and a light chain variable region of the antibody through RT-PCR. The variable region sequences are respectively inserted into a vector plasmid with constant region (heavy chain and light chain) genes, and the recombinant monoclonal antibody is obtained through transfection expression and purification. The recombinant monoclonal antibody provided in the application has high affinity with rabbit IgG, can recognize and detect rabbit IgG with high specificity and high sensitivity, and can be used as a secondary antibody after HRP cross-linking, applied to methods such as protein immunoblotting, immunohistochemistry and ELISA for detecting rabbit IgG, is conducive to obtaining more accurate detection and evaluation results, and reduces the interference of detection cost and background signal.

The application provides an incubation device for immunohistochemistry, a staining treatment all-in-one machine and a control method thereof. The device comprises a cabin body, a carrier and a condensation flow guide plate. The carrier is provided with a humidification flow channel, which is divided into multiple liquid accumulation pools by a liquid distribution baffle, and the overflow principle is used to ensure uniform humidity and inhibit liquid accumulation during movement. The condensation flow guide plate is provided with a heating surface and a condensation surface, the temperature of the condensation surface is controlled to be lower than the dew point, vapor is induced to condense on the condensation surface and is discharged to a waste liquid outlet through the flow guide surface, and condensate droplets are prevented from falling on the slide. A driving assembly drives the carrier to move between an incubation position and an operation position and drives the cabin door to move. The application combines zoned temperature control, induced condensation and physical directional flow guidance, solves the risk of sample dilution caused by random condensation of condensate in a high humidity environment, simplifies the overall structure of the machine and improves the automation integration degree.

This invention discloses the application of P4HB as a target in the preparation of therapeutic drugs for metastatic pleural and peritoneal effusions in multiple cancer types. Through combined single-cell transcriptomics and proteomics analysis, this invention revealed that P4HB is significantly overexpressed in metastatic pleural and peritoneal effusion lesions. Multiplex immunofluorescence and immunohistochemistry were used to perform in situ tissue validation in clinical samples of pleural and peritoneal effusions from breast cancer, lung cancer, gastric cancer, colorectal cancer, and ovarian cancer, clarifying the differential expression characteristics of P4HB in metastatic tumor cells and its correlation with poor prognosis. In patient-derived organoid models, targeting and inhibiting P4HB activity with small molecule inhibitors significantly reduced organoid growth capacity and survival rate, and showed a synergistic sensitizing effect on chemotherapeutic drugs. This invention reveals the use of P4HB as a therapeutic target for metastatic pleural and peritoneal effusions in multiple cancer types, providing a new target and direction for drug development in precision medicine.